Larry Leslie, MD
Interventional Cardiology · Naples, FLNPI 1669419990
Payments from drug & device makers
Across 308 payments — averaging $147.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$28K
- Johnson & Johnson$12K
- Edwards Lifesciences$1K
- Novartis$673
- Alnylam Pharmaceuticals Inc.$534
- Abiomed$447
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$34,63576%
- Travel & lodging$3,6278%
- Food & beverage$7,07016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 57 | $28,214 |
| Johnson & Johnson | 23 | $11,826 |
| Edwards Lifesciences | 43 | $1,402 |
| Novartis | 48 | $673 |
| Alnylam Pharmaceuticals Inc. | 33 | $534 |
| Abiomed | 6 | $447 |
| Cvrx, Inc. | 19 | $387 |
| Boston Scientific | 13 | $305 |
| Boehringer Ingelheim | 14 | $291 |
| Shockwave Medical, Inc | 3 | $184 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $168 |
| Abbott | 2 | $146 |
| Bayer | 7 | $145 |
| Cardiva Medical, Inc. | 3 | $128 |
| Esperion Therapeutics, Inc. | 4 | $90 |
| Novo Nordisk | 4 | $85 |
| Medtronic | 2 | $62 |
| Kestra Medical Technology Services, Inc. | 3 | $59 |
| Philips North America LLC | 1 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Inari Medical, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$27,575
- XARELTO$11,561
- Impella$290
- Vascular Lithotripsy$129
- Mitra Clip system$122
- Edwards SAPIEN 3 Transcatheter Heart Valve$109
- Barostim Neo System$107
How this compares
$45,332 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 692 | $613,122 |
| EliquisApixaban | 242 | $337,352 |
| EntrestoSacubitril/Valsartan | 209 | $309,217 |
| XareltoRivaroxaban | 220 | $264,463 |
| JardianceEmpagliflozin | 205 | $178,262 |
| OzempicSemaglutide | 144 | $141,363 |
| Praluent PenAlirocumab | 101 | $76,756 |
| MounjaroTirzepatide | 67 | $68,851 |
| WegovySemaglutide | 34 | $65,135 |
| NexletolBempedoic Acid | 62 | $31,979 |
| VascepaIcosapent Ethyl | 26 | $16,802 |
| Rosuvastatin Calcium | 1,144 | $16,724 |
| Nebivolol Hcl | 243 | $14,908 |
| Repatha SyringeEvolocumab | 15 | $14,525 |
| CrestorRosuvastatin Calcium | 13 | $9,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $337,352242 claims |
| NovartisEntresto | $673 | $309,217209 claims |
| Johnson & JohnsonXarelto | $11,826 | $264,463220 claims |
| Novo NordiskOzempic, Wegovy | $85 | $206,498178 claims |
| Boehringer IngelheimJardiance | $291 | $178,262205 claims |
| Lilly USA, LLCMounjaro | $18 | $68,85167 claims |
| Esperion Therapeutics, Inc.Nexletol | $90 | $31,97962 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Naples
- Roberto CubedduNaples$2M
- Julian JavierNaples$1.7M
- Leandro PerezNaples$386K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.